Assessment of cardiovascular risk in patients with crystal-induced arthritides and rheumatoid arthritis by the ATP III and Reynolds Risk Score

Cardiovascular risk (CVR) in patients with calcium pyrophosphate crystal deposition disease (CPPD) has not been studied, and the optimal method for assessing it has not been established yet.

Objective: Evaluation of CVR and comparison of results using Adult Treatment Panel III (ATP III) and Reynolds Risk Score (RRS) scales in patients with CPPD, gout, rheumatoid arthritis (RA) and in the control group.

Materials and methods: Cross-sectional, single-center study performed by case-control method. There are 42 patients with CPPD in main group, 42 patients with gout and RA in the comparison groups are, 42 healthy volunteers in the control group. The survey included measurements of anthropometric measures, blood pressure (BP), serum glucose, creatinine, cholesterol (TC), high density lipoproteins (HDL), low density lipoproteins (LDL), C-reactive protein (CRP). CVR was assessed on ATP III and RRS scales, comparison of its evaluation results was carried out between groups and between scales within groups.

Results and discussion: Most of the parameters in the compared groups did not differ. However, HDL CS levels were significantly higher in patients with CPPD and in the control group than in RA and gout (p<0.05). In addition, in patients with gout and RA, systolic BP was higher than in CPPD and in control (p<0.05).
CRP in CPPD was lower than in gout and RA and was not significantly different from this indicator in the control group. Its median was 3.8 [1.0; 12.4], 8.5 [4.1; 12.9] (р <0.05), 8.6 [4.1; 20.6] (р<0.05), 1.5 [0.8; 2.6] mg/l (p>0.05). The CRP > 5 mg/L in CPPD and in the control group was greater than in RA (p<0.05) and gout (p<0.05), but CRP≥5 mg/L was determined in 18 patients (43%) with CPPD and only in 3 (7%) people in the control group (p<0.05). A high and very high risk of cardiovascular disease (CVD) on the ATP III scale in CPPD was noted in 5 (12%) in gout – in 7 (17%), in RA – in 9 (21%) and in the control group – in 8 (19%) cases. Its frequency in all groups was comparable.
A high and very high risk of CVD for RRS was identified in 9 (21%), 14 (33%), 12 (29%) and 7 (17%) cases, respectively.

Conclusions: CVR under CPPD, RA and gout is comparable and quite high. The RRS scale may be a more objective method of assessing CVD risk in patients with CPPD, gout and RA.

1. OECD. Health at a Glance 2011: OECD Indicators. OECD Publishing. 2011:28. DOI:10.1787/health_glance-2011-en

2. Scarborough P., Wickramasinghe K., Bhatnagar P., Rayner M. Trends in coronary heart disease 1961–2011. British Heart Foundation: London. 2011:9–30.

3. Liao K.P. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2017;27(2):136–140. DOI: 10.1016/j.tcm.2016.07.006

4. Perez-Ruiz F., Martínez-Indart L., Carmona L., et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177–182. DOI: 10.1136/annrheumdis-2012-202421

5. Hall A.J., Stubbs B., Mamas M.A., et al. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):938–946. DOI: 10.1177/2047487315610663

6. Gerasimova E.V., Popkova T.V., Novikova D.S., et al. 10-year risk of cardiovascular complications in patients with rheumatoid arthritis. Terapevticheskii Arkhiv = Therapeutic archive. 2011;83(5):14–19 (In Russ.).

7. Crowson C.S., Rollefstad S., Ikdahl E., et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA) Ann Rheum Dis. 2018;77(1):48–54. DOI: 10.1136/annrheumdis-2017-211735

8. Gómez-Vaquero C., Robustillo M., Narváez J., et al. Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. Clin Rheumatol. 2012 Jan;31(1):35–39. DOI: 10.1007/s10067011-1774-6

9. Eliseev M.S., Denisov I.S., Markelova E.I., et al. Independent risk factors for severe cardiovascular events in male patients with gout: results of a 7-year prospective study. Terapevticheskii Arkhiv = Therapeutic archive. 2017;05:1019 (In Russ.). DOI: 10.17116/terarkh201789510-19

10. Zhang J., Chen L., Delzell E. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73(7):1301–1308. DOI: 10.1136/annrheumdis-2013-204715

11. Del Rincon I., Polak J.F., O’Leary D.H., et al. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1118–1123. DOI: 10.1136/annrheumdis-2013-205058

12. Popkova T.V., Novikova D.S., Novikov A.A., et al. The role of systemic inflammation in the development of cardiovascular complications in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Scientific and practical rheumatology. 2009;3:61 (In Russ.).

13. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 49(21):2129–2138.

14. Klyukvina N.G., Baranov Ye.L., Alexandrova E.N., Nasonov E.L. C-reactive protein in systemic lupus erythematosus in men: association with thrombotic complications. Klinicheskaya meditsina = Clinical medicine. 1997;8:24 (In Russ.).

15. Nurmohamed M.T., Heslinga M., Kitas G.D. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693–704. DOI: 10.1038/nrrheum.2015.112

16. Popkova T.V., Novikova D.S., Nasonov E.L. Cardiovascular risk factors in rheumatic diseases: link with inflammation. Consilium Medicum. 2010;12(2):112–118 (In Russ.).

17. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Piñeiro A., GarciaPorrua C., Testa A., Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1219–1223. PMID: 15996055

18. Barskova V.G., Ilyina A.E., Semenova LA., et al. Pyrophosphate arthropathy is a rheumatological iceberg syndrome: time to reassess its importance in joint diseases. Sovremennaya revmatologiy = Modern Rheumatology. 2010;4(2):5–10 (In Russ.). DOI: 10.14412/1996-7012-2010-595

19. Schlee S., Bollheimer L.C., Bertsch T., et al. Crystal arthritides gout and calcium pyrophosphate arthritis. Zeitschrift Für Gerontologie Und Geriatrie, 2017;51(4):453–460. DOI: 10.1007/s00391-017-1197-3

20. Salaffi F., De Angelis R., Grassi W.; MArche Pain Prevalence; INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23(6):819–828. PMID: 16396700

21. Richette P., Bardin T., Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology. 2009;48(7):711–715. DOI: 10.1093/rheumatology/kep081

22. Eliseev M.S., Zhelyabina O.V., Chikina M.N., Novikova A.M. Cardiovascular risk factors in patients with calcium pyrophosphate crystal deposition disease. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2019;57(5):545–552 (In Russ.). DOI: 10.14412/1995-4484-2019-545-552

23. Perk J., De Backer G., Gohlke H., et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) G Ital Cardiol (Rome). 2013;14(5):328–392. DOI: 10.1714/1264.13964

24. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:24862497. DOI: 10.1001/jama.285.19.2486

25. Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–2251. DOI: 10.1161/CIRCULATIONAHA.108.814251

26. Hollander J.L., Jessar R.A., McCarty D.J. Synovianalysis: an aid in arthritis diagnosis. Bulletin on the Rheumatic Diseases. 1961;12:263–254. PMID: 13908387

27. Kay J., Upchurch K.S. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51 Suppl 6:vi5–vi9. DOI: 10.1093/rheumatology/kes279

28. Neogi T., Jansen T.L., Dalbeth N., et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative [published correction appears in Ann Rheum Dis. 2016;75(2):473]. Ann Rheum Dis. 2015;74(10):1789–1798. DOI: 10.1136/annrheumdis-2015-208237

29. Di Lullo L., House A., Gorini A., Santoboni A., Russo D., Ronco C. Chronic kidney disease and cardiovascular complications. Heart Fail Rev. 2015;20(3):259–272. DOI: 10.1007/s10741014-9460-9

30. Kayıkçıoğlu M. Yaşlı hastalarda kardiyovasküler risk hesaplaması [Calculation of cardiovascular risk in elderly patients]. Turk Kardiyol Dern Ars. 2017;45(Suppl 5):22–24. DOI: 10.5543/tkda.2017.33803

31. D’Agostino R.B. Sr, Grundy S., Sullivan L.M., Wilson P. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–187. DOI: 10.1001/jama.286.2.180

32. Brindle P., Beswick A., Fahey T., Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752–1759. DOI: 10.1136/hrt.2006.087932

33. Beck C., Morbach H., Richl P., et al. How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int. 2009;29(3):229–238. DOI: 10.1007/s00296-008-0710-9

34. Martinon F., Pétrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241. DOI: 10.1038/nature04516

35. Nasonov E.L., Eliseev M.S. Role of interleukin 1 in the development of human diseases. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60–77 (In Russ.). DOI: 10.14412/19954484-2016-60-77

36. Dalbeth N.H.D. Pathophysiology of crystal-induced arthritis. In: Wortmann R.L. Sh. J., Becker M.A., Ryan L.M. (eds). CrystalInduced Arthropathies: Gout, Pseudogout, and ApatiteAssociated Syndromes. Taylor & Francis Group, New York, 2006. P. 239.

37. Golia E., Limongelli G., Natale F., et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 2014;16(9):435. DOI: 10.1007/s11883-0140435-z

38. Crittenden D.B., Lehmann R.A., Schneck L., et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458–1464. DOI: 10.3899/jrheum.111533

39. Nidorf S., Eikelboom J., Budgeon C., et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–410. DOI: 10.1016/j.jacc.2012.10.027

40. Tardif J.-C., Simon Kouz S., Waters D., et al. Efficacy and Safety of Low-Dose Colchicine After Myocardial Infarction. N Engl J Med. 2019;381(26):2497 –2505. DOI: 10.1056/NEJMoa1912388

41. Kajikawa M., Higashi Y., Tomiyama H., et al. Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. Int J Cardiol. 2019;281:35–39. DOI: 10.1016/j.ijcard.2019.01.054

42. Day A.L., Singh J.A. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? Drugs Aging. 2019;36(6):493–510. DOI: 10.1007/s40266-019-00653-0

43. Kim H.J., Kim M.J., Lee C.K., Hong Y.H. Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis. J Korean Med Sci. 2015;30(11):15891596. DOI: 10.3346/jkms.2015.30.11.1589

44. De Vecchis R., Baldi C., Palmisani L. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. Anatol J Cardiol. 2016;16(1):2–9. DOI: 10.5152/akd.2015.6136

45. Ridker P.M., Everett B.M., Pradhan A., et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;380(8):752–762. DOI: 10.1056/NEJMoa1809798

46. Eliseev M.S., Vladimirov S.A., Nasonov E.L. Use of methotrexate in patients with calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(2):196–201 (In Russ.). DOI: 10.14412/1995-4484-2018-196-201

47. Baghdadi L.R., Woodman R.J., Shanahan E.M., Mangoni A.A. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117952. DOI: 10.1371/journal.pone.0117952

48. Barskova V.G., Il’inykh E.V., Eliseev M.S., et al. Cardiovascular risk in patients with gout. Ozhireniye i metabolizm = Obesity and metabolism. 2006;3(3):40–44 (In Russ.). DOI: 10.14341/2071-8713-5263.

49. Capuano V., Marchese F., Capuano R., et al. Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy. J Cardiovasc Med (Hagerstown). 2017;18(3):159–164. DOI: 10.2459/JCM.0000000000000347

50. Mochizuki T., Ikari K., Yano K., Okazaki K. Five-year incidence of common comorbidities, such as hypertension, dyslipidemia, diabetes mellitus, cardiovascular disease, cerebrovascular disease and cancer, in older Japanese patients with rheumatoid arthritis. Geriatr Gerontol Int. 2019;19(7):577–581. DOI: 10.1111/ggi.13664

51. Joshi A., Siva C. Magnesium disorders can cause calcium pyrophosphate deposition disease: A case report and literature review. Eur J Rheumatol. 2018;5(1):53–57. DOI: 10.5152/eurjrheum.2017.16116